23andme.comHealthcare / Healthcare providers & servicesFounded: 2006Funding to Date: $876.61MM
23andMe is a consumer genetics and research company looking to help people access, understand, and benefit from the human genome.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/23/2020 | Series F-1 | $385MM | $xx.xx | $2.59B | Glaxosmithkline, Newview Capital, Sequoia Capital | |
Price per Share
$xx.xx
Shares Outstanding
22,190,201
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Glaxosmithkline, Newview Capital, Sequoia Capital
|
||||||
09/12/2017 | Series F | $250MM | $xx.xx | $1.75B | Altimeter Capital, Casdin Capital, Euclidean Capital, Fidelity Management, Sequoia Capital, Wallenberg Foundation | |
Price per Share
$xx.xx
Shares Outstanding
18,006,075
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Altimeter Capital, Casdin Capital, Euclidean Capital, Fidelity Management, Sequoia Capital, Wallenberg Foundation
|
||||||
06/08/2015 | Series E | $115.25MM | $xx.xx | $1.1B | Casdin Capital, Fidelity Management, Google Ventures, Illumina, Mpm Capital, New Enterprise Associates, Wuxi Venture Fund, Xfund | |
Price per Share
$xx.xx
Shares Outstanding
10,644,057
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Casdin Capital, Fidelity Management, Google Ventures, Illumina, Mpm Capital, New Enterprise Associates, Wuxi Venture Fund, Xfund
|
||||||
12/10/2012 | Series D | $58.45MM | $xx.xx | $288.74MM | Google Ventures, Mpm Capital, New Enterprise Associates, Other Individual Investors | |
Price per Share
$xx.xx
Shares Outstanding
14,435,636
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google Ventures, Mpm Capital, New Enterprise Associates, Other Individual Investors
|
||||||
11/10/2010 | Series C | $31.18MM | $xx.xx | $184.5MM | Google Ventures, Johnson & Johnson, Mpm Capital, New Enterprise Associates, Roche Venture Fund | |
Price per Share
$xx.xx
Shares Outstanding
9,898,011
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google Ventures, Johnson & Johnson, Mpm Capital, New Enterprise Associates, Roche Venture Fund
|
||||||
12/23/2009 | Series B | $27.78MM | $xx.xx | $150.5MM | Google, New Enterprise Associates, Other Individual Investors | |
Price per Share
$xx.xx
Shares Outstanding
9,048,560
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google, New Enterprise Associates, Other Individual Investors
|
||||||
05/22/2007 | Series A | $8.95MM | $xx.xx | $48.5MM | Genentech, Google Ventures, Mohr Davidow Ventures, New Enterprise Associates | |
Price per Share
$xx.xx
Shares Outstanding
7,119,936
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Genentech, Google Ventures, Mohr Davidow Ventures, New Enterprise Associates
|